What’s New

AstraZeneca Hong Kong and Lippo Healthcare Invest Together for Health Innovation and Collaboration in the Greater Bay Area

Release Date: 2021-06-15

(HK-15 June 2021) AstraZeneca Hong Kong (AZHK) and Lippo Healthcare (HK) Limited sign a Memorandum of Understanding (MOU) to commit investing and developing health innovation and patient centric solutions in the Guangdong-Hong Kong-Macao Greater Bay Area (the GBA). The cooperation will leverage their exclusive strength and network to foster the Hong Kong-GBA collaboration and accelerate the development of quality healthcare services in the GBA.

The establishment of the GBA is a national strategic project initiated by the Central Government, aiming to develop a world-class city cluster. In the healthcare sector, the initiative provides the industry with vast resources and business opportunities in the cities of the GBA. Besides, to facilitate Hong Kong residents to seek suitable healthcare services in the GBA, the recent new measure promulgated by the Central Government allows designated healthcare institutions in the GBA to use HK-registered drugs with urgent clinical use, and medical devices used in HK HA hospitals with urgent clinical use and advanced clinical applications, subject to the approval of Guangdong Province.

Hong Kong as a Regional Health Innovation Hub in GBA

Underpinned by the new government policy and the trend of integration with the GBA, the cooperation between AstraZeneca Hong Kong and Lippo Healthcare will foster the collaboration of Hong Kong-Shenzhen and other cities in the GBA, especially on chronic diseases such as cardiovascular, respiratory diseases and oncology.

By making use of the innovative drug delivery and government policies the collaboration will help to enhance healthcare access in the GBA. With the support from AstraZeneca China Healthcare IoT Innovation Centre and the connection with innovative platforms in Hong Kong, the cooperation will develop innovative solutions to address healthcare challenges in the GBA, as well as reinforce Hong Kong’s position as a key accelerator for innovation in the GBA.

Gwenael Meneux, General Manager of AstraZeneca Hong Kong & Macau, said “AstraZeneca Hong Kong formulates the strategic direction in the GBA with a staunch commitment to bring patients a better medical solution. The cooperation with Lippo Healthcare is essential for us to deliver innovative healthcare solution to address the challenges in the GBA. It also demonstrates we are committed to foster healthcare innovation in GBA. I look forward to the fruitful accomplishment brought by this cooperation, and hopefully it will become a showcase to extend collaborative opportunities with other Mainland cities.”

Mr John Lee BBS, FCA, JP, Managing Director and Chief Executive Officer, Lippo Limited, said “Lippo is committed to the provision of quality healthcare services in the Greater Bay Area and welcomes the opportunity to collaborate with AstraZeneca, a leading global pharmaceutical company well-known for its capabilities in drugs and innovative solutions, to help address the healthcare needs in this region. We hope the cooperation with AstraZeneca will help to make quality healthcare solutions and drugs accessible, affordable, and reliable to the general public in the GBA.”

(Seating from left to right)
• Mr. John Lee, BBS, FCA, JP, Managing Director and Chief Executive Officer of Lippo Limited
• Mr. Gwenael Meneux, General Manager of AstraZeneca Hong Kong & Macau

(Standing from left to right)
• Mr. Wing Chan, Executive Vice President, Corporate Finance & Development of Lippo Group
• Dr. David Ng, Director of Lippo Asia Limited
• Mr. Chris Chow, Senior Manager of Government Affairs and Market Access of AstraZeneca Hong Kong